Abstract
Abstract COPD remains to be a giant public health burden and is the third leading cause of death worldwide. The presence of eosinophilic inflammation indicates a distinct pathophysiologic phenotype in COPD with a differential risk profile and response to therapy. Blood eosinophilia, clinical judgement and other patient centred factors helps in developing individualized treatment plans for patients with COPD. Appropriate management of eosinophilic airway inflammation will have an impact on lung function decline and exacerbations, thereby causing significant improvement in morbidity and mortality associated with COPD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
